Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
2012
mi
from 43215
Tacoma, WA
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2012
mi
from 43215
Tacoma, WA
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
2026
mi
from 43215
Vancouver, WA
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2026
mi
from 43215
Vancouver, WA
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
1922
mi
from 43215
Yakima, WA
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1922
mi
from 43215
Yakima, WA
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
403
mi
from 43215
Green Bay, WI
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
403
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
363
mi
from 43215
Janesville, WI
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
363
mi
from 43215
Janesville, WI
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
335
mi
from 43215
Milwaukee, WI
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
5396
mi
from 43215
Quilmes,
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Research Site
5396
mi
from 43215
Quilmes,
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
993
mi
from 43215
Miami, FL
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
490
mi
from 43215
Poughkeepsie, NY
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
490
mi
from 43215
Poughkeepsie, NY
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
140
mi
from 43215
Mount Sterling, KY
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
140
mi
from 43215
Mount Sterling, KY
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
394
mi
from 43215
Saint Louis, MO
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
1284
mi
from 43215
Santa Fe, NM
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1284
mi
from 43215
Santa Fe, NM
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
974
mi
from 43215
The Woodlands, TX
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
974
mi
from 43215
The Woodlands, TX
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
328
mi
from 43215
Washington,
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
328
mi
from 43215
Washington,
Click here to add this to my saved trials
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Status: Enrolling
Updated:  12/31/1969
995
mi
from 43215
Houston, TX
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
746
mi
from 43215
Ocala, FL
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Ocala Oncology Center
746
mi
from 43215
Ocala, FL
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
791
mi
from 43215
Ocoee, FL
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of Florida
791
mi
from 43215
Ocoee, FL
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
371
mi
from 43215
Raleigh, NC
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of North Carolina
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
928
mi
from 43215
Arlington, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Arlington South
928
mi
from 43215
Arlington, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
925
mi
from 43215
Bedford, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
925
mi
from 43215
Bedford, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
919
mi
from 43215
Dallas, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Methodist Charlton Cancer Ctr.
919
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
902
mi
from 43215
Mesquite, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center of Mesquite
902
mi
from 43215
Mesquite, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
627
mi
from 43215
Minneapolis, MN
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
627
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
2055
mi
from 43215
Eugene, OR
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Institute/Research Ctr
2055
mi
from 43215
Eugene, OR
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
360
mi
from 43215
Greenville, SC
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
985
mi
from 43215
Waco, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care And Research Center
985
mi
from 43215
Waco, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
426
mi
from 43215
Norfolk, VA
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
426
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
1922
mi
from 43215
Yakima, WA
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
1922
mi
from 43215
Yakima, WA
Click here to add this to my saved trials
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors
Status: Enrolling
Updated:  12/31/1969
910
mi
from 43215
Dallas, TX
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors
Status: Enrolling
Updated: 12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
425
mi
from 43215
Atlanta, GA
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
425
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1335
mi
from 43215
Albuquerque, NM
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1335
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
100
mi
from 43215
Cincinnati, OH
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
100
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Anniston, AL
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from 43215
Anniston, AL
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1950
mi
from 43215
La Jolla, CA
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1950
mi
from 43215
La Jolla, CA
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
1959
mi
from 43215
Orange, CA
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
797
mi
from 43215
Orlando, FL
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
797
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
274
mi
from 43215
Chicago, IL
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
477
mi
from 43215
New York, NY
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
461
mi
from 43215
Anniston, AL
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Regional Medical Center
461
mi
from 43215
Anniston, AL
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
703
mi
from 43215
Mobile, AL
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Hospital
703
mi
from 43215
Mobile, AL
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
3101
mi
from 43215
Anchorage, AK
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center
3101
mi
from 43215
Anchorage, AK
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
3032
mi
from 43215
Fairbanks, AK
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
3032
mi
from 43215
Fairbanks, AK
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
506
mi
from 43215
Jonesboro, AR
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
NEA Medical Clinic - East Matthews
506
mi
from 43215
Jonesboro, AR
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
624
mi
from 43215
Little Rock, AR
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
2090
mi
from 43215
Castro Valley, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
East Bay Radiation Oncology Center
2090
mi
from 43215
Castro Valley, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
2090
mi
from 43215
Castro Valley, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology Consultants - Castro Valley
2090
mi
from 43215
Castro Valley, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
2082
mi
from 43215
Concord, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Cancer Care Center at John Muir Health - Concord Campus
2082
mi
from 43215
Concord, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
1955
mi
from 43215
Duarte, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
2077
mi
from 43215
Fairfield, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
North Bay Cancer Center
2077
mi
from 43215
Fairfield, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
2088
mi
from 43215
Fremont, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology
2088
mi
from 43215
Fremont, CA
Click here to add this to my saved trials